Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
2019-nCoV Vaccine mRNA-1273
Adult
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Female
Humans
Male
Mutation
Neutralization Tests
Pandemics
/ prevention & control
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Vaccination
COVID-19
SARS-CoV-2 variants of concern
mRNA-1273
neutralization
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
09 11 2021
09 11 2021
Historique:
pubmed:
23
9
2021
medline:
19
11
2021
entrez:
22
9
2021
Statut:
ppublish
Résumé
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization.
Identifiants
pubmed: 34549975
doi: 10.1128/JVI.01313-21
pmc: PMC8577347
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0131321Subventions
Organisme : Moderna, Inc.
Organisme : NIAID NIH HHS
ID : UM1 AI148373
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201500002C
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148576
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI149644
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Références
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Nature. 2021 Aug;596(7871):273-275
pubmed: 34111888
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
N Engl J Med. 2021 Jul 29;385(5):472-474
pubmed: 33979486
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
Rev Med Virol. 2021 Jul 19;:e2277
pubmed: 34286893